Role of Microparticles in Covid-19 Infection

NCT04448743 | Completed

• 1 other identifier: 7829
• Study Type: observational
• Target: 189
• Locations: 1 country
• Sites: 1

Brief Summary

Among the distinctive features of Covid-19, numerous reports have stressed the importance of vascular damages associated with coagulopathy onset. Microparticles (MPs) shed by apoptotic/stimulated cells are reliable markers of vascular damage released upon pro-inflammatory conditions and behave as active participants in the early steps of clot formation. In addition, MPs carry ACE1 and ACE2, the cell-entry receptor for SARS-Cov2 in the vasculature and up-regulate ACE1 expression in neighbouring endothelial cells. This may contribute to unopposed angiotensin II accumulation which further exacerbate tissue injury and promote both inflammation and thrombosis. The aim of the study is to evaluate the impact of circulating MPs on ACE2 expression, the cell-entry receptor for SARS-Cov2 on endothelial cells.

Conditions

COVID-19

Keywords

microparticles; microvesicles; vessel; vasculature; endothelium; coagulation; thrombosis

Outcome Measures

Primary Outcomes (1)

• Western blot measurement of ACE2 receptor expression in porcine cells

  Through study completion, an average of 1 year

Study Arms (3)

Covid-19 patients

Other: Blood sample

patients with coronary artery disease

Other: Blood sample

healthy volunteers

Other: Blood sample

Interventions

Blood sample OTHER

20 Ml blood sample

Covid-19 patients; healthy volunteers; patients with coronary artery disease

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

* Covid-19 patients * patients with coronary artery disease * healthy volunteers

You may qualify if:

• COVID-19 patients: age \> 18 yr
• SARS-COV-2 infection within 12 months and positive lupus anticoagulant
• Patients with cardiovascular risk factors: at least among
• Hypertension, Dyslipidemia, Diabetes mellitus, obesity, smoker, Healthy volunteers

You may not qualify if:

• Significant comorbidities (active cancer, auto-immune diseases…)

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Olivier MOREL

Strasbourg, 67000, France

Location

MeSH Terms

Conditions

COVID-19; Thrombosis

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 22, 2020
• First Posted: June 26, 2020
• Study Start: July 2, 2020
• Primary Completion: October 4, 2021
• Study Completion: October 4, 2021
• Last Updated: June 16, 2022

Record last verified: 2022-06

Locations

FR (1)